Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (6875)	8/1/1998 11:59:00 AM
From: Robert K.	Respond to of 17367

Some interesting stuff, some maybe related, some maybe not..........> >> The Fifth Conference Of The International Endotoxin Society September 12-15, 1998 SIMULTANEOUS SESSIONS 2A, 2B, 2C SESSION 2A - 10:15 - 12:10pm LBP AND CD14 Russell L. Dedrick, Moderator XOMA Corporation Berkeley, California Host - derived LPS antagonists Robert S. Munford University of Texas Southwestern Medical Center Dallas, Texas Molecular and cellular determinants of LPS clearance and deacylation by extravascular inflammatory exudates Jerrold P. Weiss University of Iowa College of Medicine Iowa City, Iowa Role of CD14 in the inflammatory response Sanna M. Goyert New York University Medical Center North Shore University Hospital Manhasset, New York 11:45 - 12:10pm Implications for a general role of LPS-binding proteins (CD14, LBP) in combating bacterial infections Christine B. Schett University of Greifswald Greifswald, Germany Recombinant 21 kD N-terminal fragment of human bactericidal/ permeability-increasing protein (rBPI21): progress in the clinic Patrick J. Scannon XOMA Corporation Berkeley, California